Protein / target
DNA polymerase catalytic subunit
Protein at a glance
Biological role
DNA-directed DNA polymerase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Replicates viral genomic DNA.
View complete UniProt function annotationHide complete annotation
Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication
Subcellular location
Domains and Gene Ontology detail (10)Hide
Gene Ontology
- CDNA polymerase complex
- Chost cell nucleus
- F5'-3' exonuclease activity
- FDNA binding
- FDNA polymerase activity
- FDNA-directed DNA polymerase activity
- Fnucleotide binding
- FRNA-DNA hybrid ribonuclease activity
- Pbidirectional double-stranded viral DNA replication
- PDNA-templated DNA replication
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Human herpesvirus 1 DNA polymerase inhibitor
Indicated for Eye Infections, HIV Infections, Virus Diseases
Human herpesvirus 1 DNA polymerase inhibitor
Indicated for Eye Infections, Virus Diseases
Human herpesvirus 1 DNA polymerase inhibitor
Indicated for Chickenpox, Eye Infections, Herpes Zoster, Virus Diseases
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: ACYCLOVIR (ANDA202168)
- Label change
Label change: ACYCLOVIR (ANDA215724)
- Label change
Label change: ACYCLOVIR (ANDA212252)
- Label change
Label change: ACYCLOVIR (ANDA074738)
- Label change
Label change: ACYCLOVIR (ANDA212718)
- Label change
Label change: ACYCLOVIR (ANDA213951)
- Label change
Label change: ACYCLOVIR (ANDA215669)
- Label change
Label change: ACYCLOVIR (ANDA216331)
- New publicationCD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
- New publicationKTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
- New publicationLong-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
- New publicationAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.